Results 101 to 110 of about 464,133 (328)

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Evaluation of the activity of the immune system and age-related tissue markers in Turquoise killifish \ud (Nothobranchius furzeri, Jubb 1971) \ud and their role in cell ageing\ud [PDF]

, 2010
Currently the Turquoise Killifish is considered the best animal model suitable for aging research. \ud This annual fish, from south east Africa, shows an exceptionally adaptive behaviour to dry periods: indeed, due to this extreme environmental ...
Di Cicco, Emiliano, Rossi, Giacomo
core  

Transcutaneous electrical nerve stimulation for cancer pain in adults. [PDF]

, 2008
Background Cancer-related pain is complex and multi-dimensional but the mainstay of cancer pain management has predominately used a biomedical approach. There is a need for non-pharmacological and innovative approaches.
Bennett, Michael I., Johnson, Mark I., Oxberry, Stephen G., Robb, Karen, Simpson, Karen H.   +4 more
core   +1 more source

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]

, 2020
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A, De Melo Gagliato, Débora, Jardim, Denis L, Kurzrock, Razelle, Nikanjam, Mina   +4 more
core   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

HIV drug resistance: problems and perspectives [PDF]

arXiv, 2012
Access to combination antiretroviral treatment (ART) has improved greatly over recent years. At the end of 2011, more than eight million HIV infected people were receiving antiretroviral therapy in low-income and middle-income countries. ART generally works well in keeping the virus suppressed and the patient healthy.
arxiv  

Critical behavior of an epidemic model of drug resistant diseases [PDF]

, 2003
In this work, we study the critical behavior of an epidemic propagation model that considers individuals that can develop drug resistance. In our lattice model, each site can be found in one of four states: empty, healthy, normally infected (not drug resistant) and strain infected (drug resistant) states.
arxiv   +1 more source

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients

Molecular Oncology, EarlyView.
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić, Florian Lüke, Steffi Treitschke, Andrea Coluccio, Martin Hoffmann, Giancarlo Feliciello, Adithi Ravikumar Varadarajan, Xin Lu, Kathrin Weidele, Catherine Botteron, Silvia Materna–Reichelt, Felix Keil, Katja Evert, Florian Weber, Thomas Schamberger, Michael Althammer, Jirka Grosse, Dirk Hellwig, Christian Schulz, Stephan Seitz, Peter Ugocsai, Anke Schlenska‐Lange, Roman Mayr, Ulrich Kaiser, Wolfgang Dietmaier, Bernhard Polzer, Jens Warfsmann, Kamran Honarnejad, Tobias Pukrop, Daniel Heudobler, Christoph A. Klein, Christian Werno   +31 more
wiley   +1 more source

Idiopathic noncirrhotic portal hypertension: current perspectives [PDF]

, 2016
The term idiopathic noncirrhotic portal hypertension (INCPH) has been recently proposed to replace terms, such as hepatoportal sclerosis, idiopathic portal hypertension, incomplete septal cirrhosis, and nodular regenerative hyperplasia, used to describe ...
D'AMATI, Giulia, Gioia, Stefania, Nicoletti, Valeria, PENTASSUGLIO, ILARIA, RIGGIO, Oliviero, VALENTE, MICHELE   +5 more
core   +1 more source

Slowing evolution is more effective than enhancing drug development for managing resistance [PDF]

arXiv, 2013
Drug resistance is a serious public health problem that threatens to thwart our ability to treat many infectious diseases. Repeatedly, the introduction of new drugs has been followed by the evolution of resistance. In principle there are two ways to address this problem: (i) enhancing drug development, and (ii) slowing drug resistance.
arxiv